This is a worldwide safety surveillance study of pregnancy outcomes in women with hATTR-PN who may have been exposed or were not exposed to TEGSEDI prior to or during the pregnancy and of pediatric outcomes up to 1 year of age.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Frequency of Selected Pregnancy and Fetal/Neonatal Outcomes
Timeframe: 10 years or 12 months after the last live birth whichever is later
Frequency of Selected Pregnancy Complications
Timeframe: 10 years or 12 months after the last live birth whichever is later
Ionis Pharmaceuticals